Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bicaudal C homolog 1 (BICC1) is an evolutionarily conserved, multi-domain RNA-binding protein that regulates gene expression at the post-transcriptional level. It contains several K-homology (KH) domains in its N-terminal region which confer specificity for target mRNA binding, and it can interact with the Ccr4-Not deadenylase complex to modulate mRNA stability and translation. BICC1 is important for embryonic development—especially in left-right patterning in vertebrates—by regulating the translation or decay of specific mRNAs such as **dand5, gdf3**, and **PkD2**. It can repress or, in some cases, activate specific mRNA targets, often interacting with microRNAs and their associated proteins (e.g., AGO2, Dicer) to fine-tune post-transcriptional regulation. Mutations or loss of BICC1 cause cystic kidney and liver diseases in mice and are implicated in human polycystic kidney disease. Rare fusions such as FGFR2-BICC1 occur in certain tumor types and may represent oncogenic drivers[1][2][3][4].
Not applicable; no known drugs directly target BICC1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bicaudal C homolog 1 (BICC1).